- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00329199
Pennsylvania Adolescent Intervention Research Study (PAIRStudy)
TRIAD Project: Pennsylvania Adolescent Intervention Research Study (PAIRStudy; Project 3a)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The TRIAD project aims to address the persistent and acute problem of depression in a population largely made up of low-income disadvantaged youth. There are numerous treatment studies available for depression, but few exist studying the treatment of depression via the reduction of family conflict. Through this clinical trial, we aim to investigate the efficacy of a treatment for depression for adolescents largely recruited through primary care. The primary aim of this study is to test whether Attachment-Based Family Therapy reduces depression more effectively than enhanced usual care for depression. Attachment-Based Family Therapy (ABFT) is a manualized therapy designed exclusively for anxious and depressed adolescents. Secondly, we intend to examine how reduction in family conflict mediates the effect of ABFT on depression. We will, furthermore, examine whether reduction in depression or reduction in family conflict, regardless of treatment type reduces the likelihood of smoking initiation at one year.
These aims will be accomplished through a randomized clinical trial of 240 adolescents who meet criteria for a DSM-IV depressive disorder (Major Depressive Disorder, Dysthymia, or Depression NOS). Participants will be randomized into one of two treatment conditions. The two treatment conditions are as follows: Attachment-based Family Therapy for depression or Enhanced Usual Care for Depression. Treatment for Attachment-Based Family Therapy includes anywhere from 6-12 sessions. Some of the 6-12 sessions will include the patient and or the parent meeting alone with the therapists, others will include the family meeting together for family therapy sessions. The Enhanced Usual Care condition will include referrals to outside counseling or therapy, and the number of sessions will vary by patient and practitioner desire. In addition to their treatment sessions, patients and their parents will be required to complete intake, 6-week, 12-week, 26-week, and 52-week assessments. These assessments will include a large battery of self-report measures covering numerous topics around family conflict, risk-taking behavior (including smoking) and depression. The intake, 12, 26 and 52 week assessments will include a diagnostic interview. Additionally, bi-weekly for 12 weeks, adolescent's will be asked to complete a brief set of questionnaires that will help monitor their progress and safety.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- Lehigh Valley Hospital
-
Philadelphia, Pennsylvania, United States, 19146
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213
- The Children's Hospital of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 12 to 17 years of age
- HAM-D score of > 14
- Meet diagnostic criteria for either Major Depressive Disorder, Dysthymia, or Depression NOS
- Have a parent or guardian willing to participate
Exclusion Criteria:
- Currently Suicidal
- History of mental retardation or borderline intellectual functioning
- Current psychosis
- Primary caregiver unwilling to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: SINGLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Reduction in depression as measured by the Hamilton Depression Rating Scale-17.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Smoking initiation or cessation at week 52, as measured by the Timeline Follow-Back.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Guy S Diamond, Ph.D., The Children's Hospital of Philadelphia/ University of Pennsylvania
- Principal Investigator: Donald Schwarz, M.D., Children's Hospital of Philadelphia
- Study Director: Suzanne A Levy, Ph.D., Children's Hospital of Philadelphia
Study record dates
Study Major Dates
Study Start
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAP#4100027295
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.